substituted in 1 to 4 places with OR^7, $NR^{11}R^{12}$ or C_{1-4} alkyl and in which 1 or 2 CH_2 groups are optionally and independently replaced by O, $S(O)_n$, NR^8, =N- or carbonyl, and which are optionally bridged with a methano, ethano or propano group,

R^4 is C_{1-4} alkyl, substituted with $NR^{14}R^{15}$, or

R^4 and R^5 optionally together with 2 adjacent carbon atoms form a five- or six-membered carbocyclic compound, which is optionally substituted with $NR^{14}R^{15}$,

R^5 and R^6 are, independently of one another, Hydrogen, halogen, OR^7, C_{1-4} alkyl, CF_3, or OCF_3,

R^7, R^{18} and R^{19} are, independently of one another, Hydrogen, C_{1-6} alkyl or C_{6-10} aryl, which optionally is substituted with halogen or C_{1-4} alkyl,

R^8, R^{11} and R^{12} are, independently of one another, Hydrogen, C_{1-6} alkyl, C_{6-10} aryl, which optionally is substituted with halogen or C_{1-4} alkyl, COR^{10}, CO_2R^{10}, $CONR^{18}R^{19}$ or $CSNR^{18}R^{19}$,

R^9, R^{10} and R^{20} are, independently of one another, C_{1-6} alkyl or C_{6-10} aryl, which optionally is substituted with halogen or C_{1-4} alkyl,

R^{14} and R^{15} are, independently of one another, Hydrogen, CO_2R^{20} or C_{1-6} alkyl, which optionally is substituted with halogen, hydroxy, C_{1-4} alkoxy, nitro, amino, C_{1-6} alkyl, trifluoromethyl, carboxyl, cyano, carboxamido, C_{3-7} cycloalkyl, indanyl, 1,2,3,4-tetrahydronaphthyl, C_{6-10} aryl, 5- or 6-membered heteroaryl with 1-4 nitrogen, oxygen or sulfur atoms, which are optionally annelated with benzene, whereby the aryl radical and the heteroaryl radical are optionally substituted with halogen, hydroxy, C_{1-4} alkoxy, C_{1-4} alkyl, CF_3, NO_2, NH_2, $N(C_{1-4}$ alkyl$)_2$ or carboxyl, or

R^{14} and R^{15} optionally together with the nitrogen atom of R^4 or R^4 and R^5 together form a 5- to 7-membered saturated heterocycle, which optionally comprises an oxygen, sulphur or another nitrogen atom and are

optionally substituted with C_{1-4} alkyl, phenyl, benzyl or benzoyl radical which is optionally substituted with halogen, or an unsaturated 5-membered heterocycle, which optionally contains 1-3 N atoms and is optionally substituted with phenyl, C_{1-4} alkyl, halogen or CH_2-OH, and

n is 0, 1 or 2,

or tautomeric and isomeric forms and salts of a compound of formula I.

2. (Amended) A compound according to claim 1, in which R^3 is a C_{1-5} alkylene radical, which is optionally bridged with a methano, ethano or propano group.

3. (Amended) A compound according to claim 1, in which R^1 and R^2 are hydrogen.

4. (Amended) A compound according to claim 1, in which R^4 and R^5 together with two adjacent carbon atoms form a 5- or 6-membered carbocyclic compound, which is optionally substituted with $NR^{14}R^{15}$.

6. (Twice Amended) A pharmaceutical composition comprising an effective amount of a compound according to claim 1 and a pharmaceutically acceptable vehicle or adjuvant.

7. (Twice Amended) A process for the preparation of a pharmaceutical composition comprising combining an effective amount of at least one compound according to claim 1, and at least one solid, liquid or semi-liquid excipient or auxiliary and, optionally, one or more other active compounds.

Please cancel claim 8 without prejudice or disclaimer.

9. (Amended) A method for treating a neurodegenerative disease comprising administering an effective amount of a compound according to claim 1.

10. (Amended) A process for the preparation of a compound according to claim 1, wherein a compound of formula (IIa) or (IIb) or its salt



IIa

or



IIb

wherein

R^3 to R^6 are as defined in claim 1,

R is methyl or ethyl, and

X is O or S,

is reacted with ammonia, a primary or secondary amine, a hydroxylamine and/or its derivatives, or hydrazine and/or its derivatives, and optionally then the isomers are separated and the salts are formed.

11. (Amended) A compound of the formula (IIb)



IIb

wherein

" R^3 to R^6 are as defined in claim 1,

X is O or S,

or tautomeric and isomeric forms and salts of a compound of formula (IIb).

Please add the following new claims:

--12. A method according to claim 9, wherein the neurogenerative disease is cerebral ischemia, hypoxia, multiple sclerosis, amyotrophic lateral sclerosis, Parkinson's Disease, Huntington's Disease, Korksakoff's Disease, epilepsy, vomiting, stress, sleep disorders, schizophrenia, depression, migraine, pain, hypoglycemia, dementia, Alzheimer's Disease, HIV-dementia or presenile dementia.

13. A method of treating an inflammatory disease, an auto-immune disease or a cardiovascular disease comprising administering an effective amount of a compound according to claim 1.

14. A method according to claim 13, wherein the inflammatory disease, the auto-immune disease or the cardiovascular disease is hypotension, adult respiratory distress syndrome, sepsis or septic shock, rheumatoid arthritis, osteoarthritis, insulin-dependent diabetes mellitus, inflammatory disease of the pelvis/intestine, meningitis, glomerulonephritis, acute and chronic liver disease, a disease by rejection after a transplant or psoriasis.

15. A method for inhibiting neuronal NDS, comprising administering an effective amount of a compound according to claim 1.

16. A compound according to claim 1, wherein R^1 and R^2 are, each independently, hydrogen or C_{1-6} alkyl.

17. A compound according to claim 16, wherein R^3 is a C_{1-5} alkylene radical, which is optionally bridged with a methano, ethano or propano group.--